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Summary
Objectives: This study was initiated to determine the local profile of blood culture isolates and
antibiotic sensitivities in febrile neutropenic patients following chemotherapy, and to establish if
any modifications to treatment guidelines are necessary.
Design: A total of 116 episodes of febrile neutropenia admitted to the adult hematology ward at a
university medical center in Malaysia were studied retrospectively from January 2004 to January
2005.
Results: The study showed 43.1% of febrile neutropenic episodes had established bacteremia.
Gram-negative bacteria accounted for 60.3% of isolates. Sensitivities of Gram-negative bacteria
to the antibiotics recommended in the Infectious Diseases Society of America (IDSA) guidelines
were 86.1—97.2%. Coagulase-negative staphylococci were the most common Gram-positive
organisms isolated (23.3%). The majority of these were methicillin-resistant.
Conclusions: Carbapenem monotherapy, as recommended in the 2002 IDSA guidelines, is effec-
tive treatment for the infectionsmost often encountered at our center. Combination therapy with
an aminoglycoside should be considered when using ceftazidime, cefepime or piperacillin—
tazobactam, particularly in high-risk patients. Vancomycin should be used if a Gram-positive
organism is suspected or isolated.
# 2007 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.* Corresponding author. Tel.: +60 3 79492299; fax: +60 3 79556936.
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In spite of new and exciting developments in recent years,
cytotoxic chemotherapy remains the cornerstone of treat-
ment in most hematological malignancies. The resultingPublished by Elsevier Ltd. All rights reserved.
514 N.D. Baskaran et al.neutropenia is a major cause of morbidity and mortality in
these patients. Before the advent of the antibiotic era,
mortality rates in neutropenic patients with leukemia and
Gram-negative infections were as high as 91%.1 The intro-
duction of empirical antibiotic therapy dramatically altered
the management of febrile neutropenia.2,3 The mortality
rate has fallen to as low as 7% as observed in the EORTC-
IATG (European Organisation for Research and Treatment of
Cancer-International Antimicrobial Therapy) therapeutic
trials.4
Over the last three decades, there has been considerable
change in the epidemiology of pathogens causing bacteremia
in patients with febrile neutropenia. In the 1970s, Gram-
negative infections caused 60—70% of bacteremia in neutro-
penic patients; in the 1990s, the majority of bacteremia was
due to Gram-positive cocci.5—8 This trend has been attributed
to many factors: widespread use of quinolones as prophy-
laxis,9,10 the use of long-term in-dwelling intravascular
catheters,11 increased incidence of severe mucositis as a
result of increasingly potent chemotherapy, and the use of
antacids and histamine blockers.
The fact that the epidemiology of pathogens is dynamic
makes contemporary local data extremely important when
making therapeutic decisions. Therapy in the adult hematol-
ogy unit at University Malaya Medical Centre (UMMC) has
been guided largely by external data and guidelines pub-
lished by the Infectious Diseases Society of America (IDSA).
The 2002 IDSA guidelines for the treatment of febrile neu-
tropenia recommend initial therapy with ceftazidime, cefe-
pime or a carbapenem as monotherapy, or combined with an
aminoglycoside and/or vancomycin.12 Hence, the aim of this
study was to determine local patterns and antibiotic suscept-
ibilities of the pathogens causing bacteremia in patients who
have developed febrile neutropenia after chemotherapy.
Materials and methods
A retrospective study was conducted of all patients admitted
with febrile neutropenia after chemotherapy to the adult
hematology unit at UMMC between January 1, 2004 and
January 31, 2005. Patients were included if they met all
three of the following inclusion criteria: (1) fever, defined as
a single oral temperature of 38.3 8C or an oral temperature of
38 8C lasting one hour; (2) neutropenia, defined as a neu-
trophil count of <500 cells/mm3, or a count of <1000 cells/
mm3with a predicted decrease to<500 cells/mm3 within the
next 48—72 hours; and (3) received chemotherapy prior to
the episode of febrile neutropenia. Patients who had fever
and neutropenia as a result of their underlying disease,
without having received chemotherapy, were excluded. Each
separate hospital admission for febrile neutropenia was
defined as one episode. Subsequent hospital admissions for
febrile neutropenia in the same patient were included as
separate cases.
Bacteremia was defined as 1 blood culture yielding a
pathogenic organism. If the isolate was a potential skin
contaminant (such as coagulase-negative staphylococci,
Bacillus or Corynebacterium species), all the following cri-
teria needed to be met for it to be considered significant: the
presence of an intravascular catheter, the initiation of anti-
microbial therapy, and at least one of fever, temperature<36 8C, chills, or hypotension.8 An infection was considered
to be line-associated if there was clinical evidence of line
infection, or if the criteria for bacteremia were satisfied in
the absence of other sites of infection.
All available patient records were reviewed, and demo-
graphic data collected. Microbiological results were obtained
from computerized laboratory records. The choice of empiric
antibiotic regime by the treating physicians was guided by
the IDSA guidelines.12 Monotherapy with ceftazidime, cefe-
pime or piperacillin—tazobactam was the usual first-line
treatment, with conversion to a carbapenem by day 3 if
the patient was deteriorating or still febrile. Vancomycin
or antifungal therapy was added to the regime if indicated
clinically or by microbiological findings. Antibiotic prophy-
laxis was given to 10 stem cell transplantation patients
(norfloxacin and co-trimoxazole), two T cell lymphoblastic
lymphoma/leukemia patients (co-trimoxazole as prophylaxis
against Pneumocystis jiroveci), and one patient who did not
require hospitalization during chemotherapy as decided by
the attending physicians (amoxicillin—clavulanate and cipro-
floxacin).
Antibiotic susceptibilities were assessed by disk diffusion
using Clinical and Laboratory Standards Institute guide-
lines.13 For isolates of Escherichia coli and Klebsiella spp,
extended-spectrum b-lactamase (ESBL) production was
screened for by testing ceftazidime and cefotaxime, and
confirmed with the double-disk test.14
Results
A total of 120 admissions fulfilled the inclusion criteria. Of
these, 116 were recruited into the study, and four were
excluded due to missing records.
Patient profile
Themedian age of patients was 40 years (range 16—75 years).
The ratio of males to females was almost 1:1. The majority of
patients suffered from acute myeloid leukemia (51.7%) and
non-Hodgkin’s lymphoma (27.6%). Most (83.6%) of the
patients had active disease, i.e., were either newly diag-
nosed, on treatment without having achieved remission, or
relapsed. A total of 78 patients (67.2%) were receiving
primary chemotherapy. Another ten patients (8.6%) had
had hematopoietic stem cell transplantation. The remaining
patients were receiving salvage chemotherapy. Three quar-
ters of the patients were inpatients at the onset of fever.
Seventy percent had an identifiable infective focus, the
majority of which were line-related and respiratory infec-
tions. Co-morbidities were few, and included diabetes mel-
litus (11), chronic hepatitis B (6), hypertension (4), and HIV
infection (2). Detailed patient characteristics are shown in
Table 1.
Microbiology results
The 116 episodes of febrile neutropenia studied occurred in
67 patients. Of these, 50 episodes (43.1%) were blood culture
positive, occurring in 37 patients. Of these, 35 episodes had
bacteremia with a single pathogen, 10 episodes had two
pathogens isolated, and in the remaining five episodes, three
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Table 1 Patient characteristics (N = 116)
Patient characteristics n %
Race
Chinese 79 68.1
Malay 26 22.4
Indian 9 7.8
Other 2 1.7
Underlying disease
Acute lymphoblastic leukemia 16 13.8
Acute myeloid leukemia 60 51.7
Hodgkin’s disease 3 2.6
Non-Hodgkin’s lymphoma 32 27.6
Other 5 4.3
Disease status
Remission 19 16.4
No remission 97 83.6
Treatment setting
Primary chemotherapy 78 67.2
Salvage chemotherapy 28 24.1
Bone marrow transplantation 10 8.6
Presence of co-morbidities
Yes 20 17.2
No 96 82.8
Duration of neutropenia
>7 days 62 53
Hospitalization status
Inpatient 86 74.1
Outpatient 30 25.9
Infective foci
None 34 29.3
Lines 27 23.3
Respiratory 16 13.8
Perianal 8 6.9
Gastrointestinal 8 6.9
Mucositis 10 8.6
Abscess 6 5.2
Others 7 6.0
Use of antibiotic prophylaxis
Yes 13 11.2
No 103 88.8
Table 2 Pathogens isolated from 50 episodes of febrile
neutropenia
Pathogen n % of total
isolates
Gram-negative
Escherichia coli 16 21.9
Klebsiella species 11 15.1
Enterobacter species 5 6.8
Pseudomonas aeruginosa 4 5.5
Acinetobacter baumannii 2 2.7
Proteus mirabilis 1 1.4
Stenotrophomonas maltophilia 1 1.4
Aeromonas hydrophila 1 1.4
Alcaligenes species 1 1.4
Pseudomonas species 1 1.4
Unidentified Gram-negative bacillus 1 1.4
Subtotal 44 60.3
Gram-positive
Coagulase-negative Staphylococcus 17 23.3
Bacillus species 4 5.5
Staphylococcus aureus 2 2.7
Streptococcus species 2 2.7
Enterococcus species 2 2.7
Corynebacterium species 2 2.7
Subtotal 29 39.7
Total 73 100.0or more pathogens were isolated. The pathogens and their
frequencies are shown in Table 2.
The majority, 44/73 (60.3%), were Gram-negative bac-
teria. Enterobacteriaceae were the most frequently isolated
Gram-negative organisms, and coagulase-negative staphylo-
cocci (CoNS) were the Gram-positive organisms most fre-
quently isolated. Gram-negative bacteremia was present in
35.5% of patients with acute leukemia, compared with only
8.6% of those with lymphomas ( p = 0.003). The incidence of
Gram-positive bacteremia in the leukemia group was 27.6%
versus 14.3% in the lymphoma group ( p = 0.123). Thirty-
seven percent of patients with profound neutropenia, i.e.,
absolute neutrophil count <100 cells/mm3, had Gram-nega-
tive bacteremia, compared with 19% of those with neutrophil
counts >100 cells/mm3 ( p = 0.03).Of the 13 patients taking antibiotic prophylaxis, five had
bacteremic episodes, including four post-transplant patients
on norfloxacin and co-trimoxazole, and one patient on amox-
icillin—clavulanate and ciprofloxacin. One patient had Enter-
ococcus bacteremia, while the other four had mixed Gram-
positive and Gram-negative infections. Of the five Gram-
negative isolates, comprising E. coli (3), Pseudomonas aer-
uginosa (1) and Acinetobacter species (1), all but the latter
were resistant to the antibiotic prophylaxis used. The num-
bers involved are otherwise too small to draw conclusions
about the impact of prophylaxis.
Line-related infections accounted for 23.3% of the total
source of febrile neutropenia. Of the 12 line infections that
were bacteremic, four (33.3%) yielded Gram-positive organ-
isms, five (41.7%) yielded Gram-negative organisms, and
three (25%) were mixed. Thus, line-related infections did
not appear to predispose to Gram-positive bacteremia. None
of the patients with mucositis in this series had Gram-positive
bacteremia.
Local antimicrobial sensitivity patterns
Details of the in vitro sensitivity profiles of the four most
frequently isolated Gram-negative pathogens (E. coli, Kleb-
siella spp, Enterobacter spp, and P. aeruginosa) are shown in
Table 3. These four pathogens accounted for 81.8% (36/44) of
all Gram-negative isolates. Susceptibility rates were highest
for carbapenems (94.4%), and the aminoglycosides amikacin
(97.2%) and netilmicin (94.4%).
A total of 4/44 (9.1%) of Gram-negative isolates were
resistant to imipenem and meropenem, including one strain
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Table 3 Antibiotic susceptibilities of the most frequently isolated Gram-negative organisms (Escherichia coli, Klebsiella species,
Enterobacter species and Pseudomonas aeruginosa)
Antibiotic No. susceptible (%)
E. coli
(n = 16)
Klebsiella
spp (n = 11)
Enterobacter spp
(n = 5)
P. aeruginosa
(n = 4)
Total
(n = 36)
Amoxicillin—clavulanate 9 (56.3%) 9 (81.8%) 1 (20%) 0 19 (52.8%)
Cefepime 14 (87.5%) 10 (90.9%) 4 (80%) 3 (75%) 31 (86.1%)
Ceftazidime 14 (87.5%) 10 (90.9%) 4 (80%) 3 (75%) 31 (86.1%)
Imipenem 16 (100%) 11 (100%) 4 (80%) 3 (75%) 34 (94.4%)
Meropenem 16 (100%) 11 (100%) 4 (80%) 3 (75%) 34 (94.4%)
Piperacillin—tazobactam 16 (100%) 9 (81.8%) 4 (80%) 3 (75%) 32 (88.9%)
Ciprofloxacin 6 (37.5%) 9 (81.8%) 5 (100%) 4 (100%) 24 (66.7%)
Amikacin 15 (93.8%) 11 (100%) 5 (100%) 4 (100%) 35 (97.2%)
Gentamicin 12 (75%) 11 (100%) 5 (100%) 4 (100%) 32 (88.9%)
Netilmicin 14 (87.5%) 11 (100%) 5 (100%) 4 (100%) 34 (94.4%)each of Stenotrophomonas maltophilia, Aeromonas hydro-
phila, P. aeruginosa, and Enterobacter spp. Of 27 E. coli and
Klebsiella spp, three (11.1%) were ESBL-producers. The total
ceftazidime and cefepime sensitivity rate for the four main
Gram-negative pathogens was 86.1%.
All Gram-positive isolates were sensitive to vancomycin. Of
the 17 CoNS isolated, 76% weremethicillin-resistant. Both the
isolates of Staphylococcus aureus were methicillin-sensitive.
Discussion
In order to effectively treat infections in the neutropenic
patient with fever, knowledge of the likely pathogens and the
local antibiotic sensitivity patterns in individual centers is
crucial. The etiology of bacteremia in febrile neutropenic
patients after being given chemotherapy in this study was
predominantly Gram-negative (60.3%), with E. coli, Kleb-
siella spp, Enterobacter spp and P. aeruginosa the most
frequently isolated organisms. Similar results have been
found in some European centers, which have reported the
reemergence of Gram-negative bacilli as predominant patho-
gens; this may partly be due to decreased use of quinolone
prophylaxis.7 Apart from stem cell transplantation patients
and Pneumocystis prophylaxis in patients with Tcell lympho-
blastic lymphoma/leukemia, prophylaxis is not routinely
used in our center. Therefore, the initial choice of empirical
therapy at our center must have adequate Gram-negative
and anti-pseudomonal coverage. Our susceptibility results
suggest that monotherapy with a carbapenem is a viable
treatment strategy. When using ceftazidime, cefepime or
piperacillin—tazobactam, the addition of an aminoglycoside,
preferably amikacin, is advisable. Concern regarding renal
toxicity should not prohibit the use of these agents as our
patient population is young, with few co-morbidities, and
99% had a baseline serum creatinine of <180 mmol/l.
Surveillance is also important for the monitoring of rates
of resistant organisms, such as ESBL-producers and carbape-
nem-resistant Enterobacteriaceae. Although the latter are
still relatively rare,15 the isolation of a carbapenem-resistant
Enterobacter from the bloodstream of one patient is of great
concern. Similarly, our 11.1% rate of ESBL-producers amongst
E. coli and Klebsiella spp is worrying, as others have reportedan increasing incidence of serious infections caused by ESBL-
producers.7,16
The Gram-positive pathogens most commonly isolated
were CoNS with a high rate of methicillin resistance
(76%), consistent with previous data.8 The numbers of S.
aureus and Streptococcus spp infections in this study were
small, with only two isolates each, thus any comment on the
sensitivity patterns of these organisms would be invalid.
Vancomycin should still be the empirical treatment of choice
when a Gram-positive pathogen is suspected clinically, or
cultured. Therapy should be reviewed once cultures are
available.
The significantly higher rates of bacteremia in the acute
leukemia group compared to the lymphoma group in this
study, is also not surprising. This is likely due to the more
myelosuppressive chemotherapy, which usually results in a
longer duration of neutropenia, a known risk factor for
developing infections.17 Profound neutropenia is also a risk
factor for developing infection and again this has been
demonstrated in many studies.
This study only looked at those patients who had devel-
oped febrile neutropenia after chemotherapy, to determine
more accurately the possible infections in our hospital rather
than those infections from the community. This may not
represent the reality of all patients who have febrile neu-
tropenia, especially patients who are newly diagnosed with
acute leukemia. It is important to realize the limitations of
this study.
In patients who have febrile neutropenia after chemother-
apy, it is important for the attending clinicians to risk-stratify
the patients in order to prevent any fatal complications from
infection. Further study and extrapolation of the local data
will be helpful for risk stratification-based management.
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